Agent Description
Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa.
Mechanism of Action
CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T cell responsiveness, including the anti-tumor immune response.
Classification
Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86.
Molecular Target
N/A
Monograph
View the ipilimumab package insert (PDF).
Studies of Interest
Areas of Interest
Bladder: studies in various lines of therapy with nivolumab/ipilimumab plus standard of care (BCG, chemo)
Areas NOT of Interest
- Ipilimumab monotherapy in metastatic melanoma patients (exception is ipilimumab in patients whose cancer progressed on anti-PD1)
- Ipilimumab monotherapy in adjuvant stage 3 melanoma patients (exception is special populations like mucosal and uveal)
- Ipilimumab combinations with standard of care in metastatic melanoma
- Ipilimumab combinations with radiation in melanoma
- Nivolumab/ipilimumab/cabozantinib combination in renal cell carcinoma
Information collaborator would like included in investigator proposals
N/A